A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

NCT05520567 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
FLT3-mutated Acute Myeloid Leukemia

Interventions

DRUG: Gilteritinib
DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

Astellas Pharma Global Development, Inc.